Updates in the systemic treatment of hepatocellular carcinoma

Emerson Y. Chen; Charles D. Lopez; Gina M. Vaccaro

doi:10.17925/ohr.2018.14.2.76

Updates in the systemic treatment of hepatocellular carcinoma

Emerson Y. Chen, Charles D. Lopez, Gina M. Vaccaro

Research output: Contribution to journal › Review article › peer-review

Abstract

Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

Original language	English (US)
Pages (from-to)	76-81
Number of pages	6
Journal	European Oncology and Haematology
Volume	14
Issue number	2
DOIs	https://doi.org/10.17925/ohr.2018.14.2.76
State	Published - 2018

Keywords

Advanced disease
Cabozantinib
Hepatocellular carcinoma
Lenvatinib
Nivolumab
Ramucirumab
Regorafenib
Sorafenib

ASJC Scopus subject areas

Hematology
Oncology

Access to Document

10.17925/ohr.2018.14.2.76

Cite this

@article{d0f53d4ed25b4831a512af1185cd0080,

title = "Updates in the systemic treatment of hepatocellular carcinoma",

abstract = "Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.",

keywords = "Advanced disease, Cabozantinib, Hepatocellular carcinoma, Lenvatinib, Nivolumab, Ramucirumab, Regorafenib, Sorafenib",

author = "Chen, {Emerson Y.} and Lopez, {Charles D.} and Vaccaro, {Gina M.}",

year = "2018",

doi = "10.17925/ohr.2018.14.2.76",

language = "English (US)",

volume = "14",

pages = "76--81",

journal = "European Oncology and Haematology",

issn = "2045-5275",

publisher = "Touch Digital Media",

number = "2",

}

TY - JOUR

T1 - Updates in the systemic treatment of hepatocellular carcinoma

AU - Chen, Emerson Y.

AU - Lopez, Charles D.

AU - Vaccaro, Gina M.

PY - 2018

Y1 - 2018

N2 - Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

AB - Oncology drug development has recently introduced new systemic treatment options for hepatocellular carcinoma (HCC). Here we consider the general approaches to diagnostic workup, staging, and overall management of HCC with emphasis on systemic treatment options based on recent phase III clinical trials. Novel drug targets involving immunotherapy may change how we treat HCC in the near future.

KW - Advanced disease

KW - Cabozantinib

KW - Hepatocellular carcinoma

KW - Lenvatinib

KW - Nivolumab

KW - Ramucirumab

KW - Regorafenib

KW - Sorafenib

UR - http://www.scopus.com/inward/record.url?scp=85057822943&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057822943&partnerID=8YFLogxK

U2 - 10.17925/ohr.2018.14.2.76

DO - 10.17925/ohr.2018.14.2.76

M3 - Review article

AN - SCOPUS:85057822943

SN - 2045-5275

VL - 14

SP - 76

EP - 81

JO - European Oncology and Haematology

JF - European Oncology and Haematology

IS - 2

ER -

Updates in the systemic treatment of hepatocellular carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this